Sign Out
RETROVIR is indicated for use in HIV-positive pregnant women (over 14 weeks of gestation) and their newborn infants, as it has been shown to reduce the rate of maternal-foetal transmission of HIV (see Use in Pregnancy & Lactation).
Syrup: RETROVIR is indicated in combination with other anti-retroviral agents for the treatment of Human Immunodeficiency Virus (HIV) infection in adults and children.
IV infusion: RETROVIR I.V. for infusion is indicated for the short-term management of serious manifestations of Human Immunodeficiency Virus (HIV) infection in patients with Acquired Immune Deficiency Syndrome (AIDS), who are unable to take RETROVIR oral formulations.
